Company Description
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates.
The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024.
The company was incorporated in 2005 and is based in San Mateo, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 14, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vincent Angotti |
Contact Details
Address: 1850 Gateway Drive, Suite 175 San Mateo, California 94404 United States | |
| Phone | 650 216 3500 |
| Website | talphera.com |
Stock Details
| Ticker Symbol | TLPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001427925 |
| ISIN Number | US00444T2096 |
| Employer ID | 41-2193603 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vincent J. Angotti | Chief Executive Officer and Director |
| Raffi Mark Asadorian | Chief Financial Officer |
| Anil N. Dasu | Chief Engineering Officer |
| Dr. Shakil Aslam M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2025 | ARS | Filing |
| Sep 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 16, 2025 | SCHEDULE 13G | Filing |
| Sep 15, 2025 | D | Notice of Exempt Offering of Securities |
| Sep 12, 2025 | SCHEDULE 13D | Filing |
| Sep 12, 2025 | SCHEDULE 13G | Filing |
| Sep 10, 2025 | 8-K | Current Report |
| Sep 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 29, 2025 | PRE 14A | Other preliminary proxy statements |